Journal of Clinical Oncology
Articles in this Issue
Single center retrospective analysis of neoadjuvant therapy in resectable pancreatic adenocarcinoma.
e16467 Background: Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers and is expected to become the...
Efficacy of immune checkpoint inhibitors (ICIs) in locoregionally advanced nasopharyngeal carcinoma (LA NPC): A meta-analysis of phase II and III randomized controlled trials.
e18068 Background: Locoregionally advanced nasopharyngeal carcinoma (LA NPC) is primarily managed with definitive chemorad...
Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
8514 Background: SSGJ-707 is a fully human IgG4 bispecific antibody that simultaneously binds PD-1 and VEGF. In the phase...
Should CDK4/6 inhibitor plus endocrine therapy be standard of care for ER-low (1–10%) HR+/HER2− metastatic breast cancer? A multicenter registry cohort.
1102 Background: ER-low (1–10%) HR+/HER2− metastatic breast cancer (MBC) is increasingly recognized as a distinct clinical...
Plasma epigenomic profiling for identification of mechanisms of sensitivity, primary and acquired resistance to tepotinib in METex14 skipping metastatic NSCLC.
8637 Background: MET exon 14 skipping mutations (METex14) are an actionable biomarker in a subset (3-4...
The impact of MRD and post-remission strategies on outcomes following dose-dense mini-hyper-CVD inotuzumab and blinatumomab in relapsed B-cell acute lymphoblastic leukemia.
6516 Background: Advances in immunotherapy have improved outcomes for relapsed/refractory (R/R) B-cell acute lymphoblastic...
Clinical translation of PeptiCRAd-1: Interim clinical evaluation of a modular oncolytic adenovirus vaccine platform targeting NY-ESO-1 and MAGE-A3 in advanced solid tumors.
2604 Background: Oncolytic viruses can convert poorly immunogenic tumors into inflamed, immune-responsive lesions, but cli...
Real-world (RW) characteristics and outcomes in platinum-resistant ovarian cancer (PROC) patients treated with mirvetuximab soravtansine (MIRV) monotherapy or single-agent chemotherapy (CTx).
e17606 Background: The phase 3 MIRASOL trial showed that MIRV significantly improved median PFS (5.62 mo) and OS (16.46 mo...
A phase II study of neoadjuvant cemiplimab in hedgehog inhibitor (HHI)–naive basal cell carcinoma of the head and neck.
9515 Background: Surgical resection of locally advanced basal cell carcinoma of the head and neck (BCCHN) often carries si...
Validation of prostate-specific antigen (PSA) decline among the Latin American subgroup of LIBERTAS: A phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).
5021 Background: APA in combination with continuous ADT showed rapid and deep PSA decline in participants (pts) with mCSPC...
Phase 1/2 OMAHA-U01 substudy 01A: Oral steroidogenesis inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
TPS5140 Background: mCRPC remains an incurable disease and therapeutic agents with novel mechanisms of action are needed f...
A HER2-targeted NIR-II fluorescent nanoprobe for precision diagnosis and treatment of HER2-positive breast cancer.
e13026 Background: Breast cancer is the most common malignancy and a leading cause of cancer mortality worldwide. HER2-pos...
Impact of access to effective post-progression therapies on survival outcomes in first-line randomized oncology trials.
1500 Background: Effective anticancer systemic therapies are expected to improve overall survival (OS) or quality...
Survival outcomes associated with EGFR and HER2 alterations in advanced urothelial carcinoma treated with novel therapeutics.
e16571 Background: The efficacy of targeted therapies against EGFR and HER2 (ERBB2) has been investigated across multiple...
Outcome comparison of once versus twice daily dosing of zanubrutinib.
7049 Background: Zanubrutinib, a Bruton tyrosine kinase inhibitor (BTKi), approved as frontline treatment in chronic lymph...
GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.
5532 Background: Adoptive cell therapy with autologous TILs has shown durable clinical benefit in selected advanced solid...
Genomic classifier–driven NCCN risk reclassification to track distinct transcriptomic signatures in early prostate cancer.
5013 Background: NCCN clinicopathologic risk stratification in early prostate cancer (EPC) may under- or overestimate biol...
Real-world outcomes of larotrectinib in solid tumors with tropomyosin receptor kinase fusion (GETNE S2411/SPAINTRK).
e23344 Background: NTRK gene fusions have been described as oncogenic drivers in diverse adult and pae...
Mortality trends: Colorectal carcinoma associated with tobacco use as a cause of death in the United States—A CDC WONDER analysis (1999-2023).
e15659 Background: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the United States (U...
DOACs versus vitamin K antagonists for cancer-associated VTE: Updated systematic review and meta-analysis.
e23324 Background: Cancer-associated venous thromboembolism (VTE) remains a major driver of morbidity and mortality, and a...
Safety and antitumor activity of VRN110755, a brain-penetrant, selective EGFR inhibitor, in patients with EGFR-driven non–small cell lung cancer.
8623 Background: Third-generation EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes in EGFR-mutant non–small c...
Comparative analysis of hereditary cancer genetic testing programs in India and the US: Identifying disparities and guiding global program development.
e13531 Background: Identifying actionable pathogenic variants in hereditary cancer genes is critical to assess eligibility...
Simultaneous anthracycline-based chemotherapy and dual HER2 blockade in early-stage HER2-positive breast cancer: A retrospective analysis.
e12741 Background: Early-stage HER2-positive breast cancer represents a biologically aggressive subtype; however, outcomes...
Updated results of the phase 1 dose escalation and expansion study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.
8096 Background: Alveltamig (ZG006) is a uniquely designed T cell engager, targeting two distinct delta-like ligand 3 (DLL...
Duffy-null status and cytopenias following BCMA-directed CAR T therapy in multiple myeloma.
7549 Background: Anti-BCMA chimeric antigen receptor T-cell (CAR T) therapies are highly effective in relapsed or refracto...